Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit

By Bryan Koenig · August 28, 2024, 7:33 PM EDT

Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In re Xyrem (Sodium Oxybate) Antitrust Litigation

Case Number

3:20-md-02966

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

December 16, 2020

Featured Stories

Incora Uptier Fight Lays Bare Risks For Private Equity Backers No Photo Available

Alex Wittenberg

In the bruising battles for position among lenders to debt-laden companies, private equity firms often remain relatively unscathed. Bu... (more story)

The Onion's Infowars Bid Rests On Whether Highest Is Best No Photo Available

Ben Zigterman

As satirical media company The Onion prepares to defend its offer to buy Alex Jones' right-wing conspiracy show, Infowars, it is relyi... (more story)

How Spirit Airlines Landed In Bankruptcy Court No Photo Available

Emlyn Cameron

Ultra-low-cost airline Spirit has always been more susceptible to inflationary pressures than its costlier competitors, but its failed... (more story)